株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ペプチド治療の世界市場 (用途別・投与経路別・販売方式別):世界の産業分析・規模・シェア・動向・予測 (2014〜2020年)

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

発行 Transparency Market Research 商品コード 264243
出版日 ページ情報 英文 104 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
ペプチド治療の世界市場 (用途別・投与経路別・販売方式別):世界の産業分析・規模・シェア・動向・予測 (2014〜2020年) Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
出版日: 2015年04月27日 ページ情報: 英文 104 Pages
概要

当レポートでは、世界のペプチド治療市場について、用途別、投与経路別、販売方式別、タイプ、APIペプチドおよび技術別に調査すると共に、地域別の市場動向や主要企業のプロファイルをも盛り込んでお届け致します。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 世界のペプチド治療市場の概要

  • イントロダクション
  • ペプチド治療市場の新たな動向
    • ペプチド製造技術の動向
    • ペプチド医薬原体 (API) の供給の動向
  • 市場力学
    • 促進要因
      • がん患者・糖尿病患者の人口増加による、新種ペプチド市場の成長促進
      • ペプチド治療の巨大な研究開発 (R&D) パイプラインによる市場成長促進
      • 技術進歩によるペプチド製造コストの引き下げ
    • 抑制要因
      • ペプチド構造の複雑化:APIメーカーにとっての大きな課題
      • 規制基準の欠落
    • 機会
      • パテントクリフに伴うジェネリック・ペプチド市場の成長見通し
      • バイオテクノロジー企業と大手製薬企業との提携による、さらなる成長の見通し
  • 規制シナリオ
  • ポーターのファイブフォース分析:世界のペプチド治療市場
  • イベント影響度の分析
  • 市場の誘因性の分析
  • 市場シェア分析

第4章 世界のペプチド治療市場:用途別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:用途別 (通算9年間分)
  • がん
    • Zoladex (ゴセレリン)
    • Velcade (ボルテゾミブ)
    • Lupron/ Enantone/ Eligard (リュープロレリン)
    • その他
  • 心血管
    • Angiomax (ビバリルジン)
    • Integrilin (エプチフィバチド)
  • 中枢神経系
    • Copaxone (ガラティラメル)
  • 代謝障害
    • Victoza (リラグルチド)
    • Byetta (エクセナチド)
    • その他
  • 感染症
    • Incivek (テラプレビル)
    • Victrelis (ボセプレビル)
  • 血液疾患
    • Firazyr (イカチバント)
    • Kalbitor (エカランチド)
  • 胃腸障害
    • Gattex (テデュグルチド)
    • Linzess (リナクロチド)
  • 呼吸器系障害
  • 末端肥大症
  • その他の用途

第5章 世界のペプチド治療市場:投与経路別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:投与経路別 (通算9年間分)
  • 非経口投与経路
  • 経口投与経路

第6章 (ステータスを提供することによって)、世界のペプチド治療市場:販売方式別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:販売方式別 (通算9年間分)
  • ブランド・ペプチド薬治療
  • ジェネリック・ペプチド薬治療

第7章 世界のペプチド治療パイプライン製品:概要

  • イントロダクション
    • 世界のペプチド治療パイプライン製品の概要

第8章 世界のペプチド治療市場:地域別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:地域別 (通算9年間分)
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域 (ROW)

第9章 提言

  • 厳密な研究開発 (R&D) 活動による新製品の獲得
  • 新興経済国での施設拡張
  • 企業買収を通じた急速な無機的成長

第10章 企業プロファイル

  • Amgen Inc.
    • 企業概要
    • 財務概要
    • 製品ポートフォリオ
    • 事業戦略
    • 最近の発展動向
  • AstraZeneca plc
  • Bachem Holding AG
  • CordenPharma International GmbH
  • Eli Lilly and Company
  • Ipsen S.A.
  • Lonza Group Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Novo Nordisk A/S
  • PolyPeptide Group
  • Roche Holdings AG
  • Sanofi
  • 武田薬品工業
  • Teva Pharmaceutical Industries Ltd.

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography. Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Market size and forecast for leading drugs such as Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been included along with in-depth market analysis. Segmentation by marketing status explains the impact of generic drugs on the overall peptide therapeutics market. Further, market segmentation of peptide drugs by route of administration provides quantitative insights into the growing demand for convenient methods for peptide drug administration. Details on peptide drug approvals, patent expiry, mergers, acquisitions, strategic agreements, disease prevalence and other major events have been included in respective market segments.

The global peptide therapeutics market report provides market estimation and forecast for more than fifteen branded peptide drugs in the market. Further, the market is also segmented by major geographical regions, which include North America, Europe, Asia Pacific and Rest of the World. A list of pipeline drugs has also been provided in the report. This list includes potential peptide drugs in phases I, II, and III of clinical development.

Emerging trends in global peptide API production, such as development of new peptide API production technologies and strategic agreements in peptide API production have been discussed. The report also profiles key peptide API suppliers. An overview of regulatory policies has also been provided in the global peptide therapeutics market report. Based on our in-depth analysis and comprehensive market study, key factors driving and restraining the market have been discussed. A detailed event impact analysis considers regulatory approvals, patent expiry of major drugs, drug recalls and other factors in the peptide therapeutics market. The research study also incorporates the competitive scenario in these regions, where market share of seven major players in 2013 has also been provided. Relevant recommendations have been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. Fifteen major players have been profiled which include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly & Co., Ipsen S.A., Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. The 104 pages global peptide therapeutics market report includes 30 figures and charts, and 14 tables.

Market size and forecast in terms of USD million for each segment in the global peptide therapeutics market has been provided for the period 2012 to 2020, considering 2012 and 2013 as the base years. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. The peptide therapeutics market has been estimated using a bottom-up approach, where market size estimates for each drug have been summed-up to arrive at the total market size. Market forecasts have been derived considering the effect of generic drug approvals, drug recalls, disease prevalence, patent term extension, box warning and various other factors. Inputs from industry experts and key opinion leaders have validated and further refined our market estimates.

The global peptide therapeutics market has been segmented as below:

Global Peptide Therapeutics Market, by Application

  • Cancer
    • Zoladex (goserelin)
    • Velcade (bortezomib)
    • Lupron/ Enantone/ Eligard (leuprorelin)
    • Others
  • Cardiovascular
    • Angiomax (bivalirudin)
    • Integrilin (eptifibatide)
  • Central Nervous System
    • Copaxone (glatiramer)
  • Metabolic Disorders
    • Victoza (liraglutide)
    • Byetta (exenatide)
    • Others
  • Infection
    • Incivek (telaprevir)
    • Victrelis (boceprevir)
  • Hematological Disorders
    • Firazyr (icatibant)
    • Kalbitor (ecallantide)
  • Gastrointestinal Disorders
    • Gattex (teduglutide)
    • Linzess (linaclotide)
  • Respiratory Disorders
  • Acromegaly
  • Other Applications

Global Peptide Therapeutics Market, by Route of Administration

  • Parenteral
  • Oral

Global Peptide Therapeutics Market, by Marketing Status

  • Branded
  • Generic

Global Peptide Therapeutics Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
  • 1.4 List of Abbreviations
  • 1.5 Assumptions and Stipulations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
  • 2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview

  • 3.1 Introduction
  • 3.2 Emerging Trends in Peptide Therapeutics Market
    • 3.2.1 Trends in Peptide Manufacturing Technology
    • 3.2.2 Trends in Peptide API Supply
  • 3.3 Market Dynamics
    • 3.3.1 Drivers
      • 3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
      • 3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
      • 3.3.1.3 Technological advancements have reduced total production cost of peptides
    • 3.3.2 Restraints
      • 3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
      • 3.3.2.2 Lack of regulatory standards
    • 3.3.3 Opportunities
      • 3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
      • 3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
  • 3.4 Regulatory Scenario
  • 3.5 Porter's Five Forces Analysis: Global Peptide Therapeutics Market
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyer
    • 3.5.3 Threat of Substitutes
    • 3.5.4 Threat of New Entrants
    • 3.5.5 Competitive Rivalry
  • 3.6 Event Impact Analysis
    • 3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
  • 3.7 Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
  • 3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications

  • 4.1 Introduction
    • 4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 - 2020 (USD Million)
  • 4.2 Cancer
    • 4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.2 Zoladex (goserelin)
    • 4.2.3 Velcade (bortezomib)
    • 4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
    • 4.2.5 Others
  • 4.3 Cardiovascular
    • 4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.2 Angiomax (bivalirudin)
    • 4.3.3 Integrilin (eptifibatide)
  • 4.4 Central Nervous System
    • 4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.4.2 Copaxone (glatiramer)
  • 4.5 Metabolic Disorders
    • 4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.5.2 Victoza (liraglutide)
    • 4.5.3 Byetta (exenatide)
    • 4.5.4 Others
  • 4.6 Infection
    • 4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.6.2 Incivek (telaprevir)
    • 4.6.3 Victrelis (boceprevir)
  • 4.7 Hematological Disorders
    • 4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.7.2 Firazyr (icatibant)
    • 4.7.3 Kalbitor (ecallantide)
  • 4.8 Gastrointestinal Disorders
    • 4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.8.2 Gattex (teduglutide)
    • 4.8.3 Linzess (linaclotide)
  • 4.9 Respiratory Disorders
    • 4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 4.10 Acromegaly
    • 4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 4.11 Other Applications
    • 4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration

  • 5.1 Introduction
    • 5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
  • 5.2 Parenteral Route of Administration
    • 5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
  • 5.3 Oral Route of Administration
    • 5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status

  • 6.1 Introduction
    • 6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
  • 6.2 Branded Peptide Therapeutics
    • 6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.3 Generic Peptide Therapeutics
    • 6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview

  • 7.1 Introduction
    • 7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography

  • 8.1 Introduction
    • 8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 8.2 North America
    • 8.2.1 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 8.5 Rest of the World
    • 8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 9 Recommendations

  • 9.1 Rigorous research and development (R&D) would yield new products
  • 9.2 Facility expansion in emerging economies
  • 9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles

  • 10.1 Amgen, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Financial Overview
    • 10.1.3 Product Portfolio
    • 10.1.4 Business Strategies
    • 10.1.5 Recent Developments
  • 10.2 AstraZeneca plc
    • 10.2.1 Company Overview
    • 10.2.2 Financial Overview
    • 10.2.3 Product Portfolio
    • 10.2.4 Business Strategies
    • 10.2.5 Recent Developments
  • 10.3 Bachem Holding AG
    • 10.3.1 Company Overview
    • 10.3.2 Financial Overview
    • 10.3.3 Product Portfolio
    • 10.3.4 Business Strategies
    • 10.3.5 Recent Developments
  • 10.4 CordenPharma International GmbH
    • 10.4.1 Company Overview
    • 10.4.2 Financial Overview
    • 10.4.3 Product Portfolio
    • 10.4.4 Business Strategies
    • 10.4.5 Recent Developments
  • 10.5 Eli Lilly and Company
    • 10.5.1 Company Overview
    • 10.5.2 Financial Overview
    • 10.5.3 Product Portfolio
    • 10.5.4 Business Strategies
    • 10.5.5 Recent Developments
  • 10.6 Ipsen S.A.
    • 10.6.1 Company Overview
    • 10.6.2 Financial Overview
    • 10.6.3 Product Portfolio
    • 10.6.4 Business Strategies
    • 10.6.5 Recent Developments
  • 10.7 Lonza Group Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Financial Overview
    • 10.7.3 Product Portfolio
    • 10.7.4 Business Strategies
    • 10.7.5 Recent Developments
  • 10.8 Merck & Co., Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Financial Overview
    • 10.8.3 Product Portfolio
    • 10.8.4 Business Strategies
    • 10.8.5 Recent Developments
  • 10.9 Novartis AG
    • 10.9.1 Company Overview
    • 10.9.2 Financial Overview
    • 10.9.3 Product Portfolio
    • 10.9.4 Business Strategies
    • 10.9.5 Recent Developments
  • 10.10 Novo Nordisk A/S
    • 10.10.1 Company Overview
    • 10.10.2 Financial Overview
    • 10.10.3 Product Portfolio
    • 10.10.4 Business Strategies
    • 10.10.5 Recent Developments
  • 10.11 PolyPeptide Group
    • 10.11.1 Company Overview
    • 10.11.2 Financial Overview
    • 10.11.3 Product Portfolio
    • 10.11.4 Business Strategies
    • 10.11.5 Recent Developments
  • 10.12 Roche Holdings AG
    • 10.12.1 Company Overview
    • 10.12.2 Financial Overview
    • 10.12.3 Product Portfolio
    • 10.12.4 Business Strategies
    • 10.12.5 Recent Developments
  • 10.13 Sanofi
    • 10.13.1 Company Overview
    • 10.13.2 Financial Overview
    • 10.13.3 Product Portfolio
    • 10.13.4 Business Strategies
    • 10.13.5 Recent Developments
  • 10.14 Takeda Pharmaceutical Company Limited
    • 10.14.1 Company Overview
    • 10.14.2 Financial Overview
    • 10.14.3 Product Portfolio
    • 10.14.4 Business Strategies
    • 10.14.5 Recent Developments
  • 10.15 Teva Pharmaceutical Industries Ltd.
    • 10.15.1 Company Overview
    • 10.15.2 Financial Overview
    • 10.15.3 Product Portfolio
    • 10.15.4 Business Strategies
    • 10.15.5 Recent Developments

List of Figures

  • FIG. 1 Peptide Therapeutics Market Segmentation
  • FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
  • FIG. 3 Porter's Five Forces Analysis: Global Peptide Therapeutics Market
  • FIG. 4
  • FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
  • FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
  • FIG. 7 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 10 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
  • FIG. 11 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)
  • FIG. 12 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 15 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 17 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 18 Amgen, Inc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 19 AstraZeneca plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 20 Bachem Holding AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 22 Ipsen S.A.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 25 Novartis AG Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 27 Roche Holdings AG: Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 28 Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
  • TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market
  • TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 - 2020 (USD Million)
  • TABLE 4 Global Cancer Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 7 Global Infection Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 8 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 10 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
  • TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
  • TABLE 13 Global Peptide Therapeutics Market Pipeline Overview
  • TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top